<DOC>
	<DOCNO>NCT02387203</DOCNO>
	<brief_summary>The purpose study determine impact antibiotic therapy disease progression overall survival patient Pseudomyxoma Peritonei ( PMP ) .</brief_summary>
	<brief_title>Antibiotic Treatment Long-term Outcomes Patients With Pseudomyxoma Peritonei Appendiceal Origin</brief_title>
	<detailed_description>Single center , open label , historical control , phase II study propose two course standard H. Pylori eradication antibiotic therapy suppress carcinogenesis improve long-term outcome patient PMP . The first course antibiotic ( PrevPac ) administer cytoreductive surgery HIPEC second course afterwards . The historical control group consist PMP patient Mercy Medical Center 's Tumor Registry receive perioperative antibiotic treatment . Long-term statistical outcome calculate use Kaplan-Meier method Cox proportional hazard ratio compare pertinent variable . 80 subject enrol 2 year , 5 year follow-up period .</detailed_description>
	<mesh_term>Pseudomyxoma Peritonei</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Patients must measurable pseudomyxoma peritonei appendiceal origin , confirm histology , cytology , radiographical evidence Age ≥ 21 year Eastern Cooperative Onocology Group ( ECOG ) performance status score≤2/Karnofsky performance status ( KPS ) ≥ 70 % ( see Appendix B ) Patients must normal organ marrow function define : Absolute neutrophil count ( ANC ) ≥1,000/mm3 Platelets ≥100,000/mm3 Hemoglobin ≥ 8.5 g/dL Renal function : Creatinine ≤1.5 time upper limit normal ( ULN ) calculate creatinine clearance ≥60ml/min Hepatic function : Bilirubin ≤1.5 time ULN ALT ≤3 time ULN AST ≤3 time ULN Ability subject Legally Authorized Representative ( LAR ) understand willingness sign write informed consent , approve Mercy Medical Center Institutional Review Board ( IRB ) A negative pregnancy test woman childbearing age reproductive organ intact Patients receive investigational agent Presence invasive malignancy evidence another cancer present within last 3 year , exclude skin cancer history , know allergic reaction/hypersensitivity PREVPAC component similar chemical biologic composition PREVPAC Patients &lt; 21 age Pregnancy lactation time propose assignment . Pregnant woman exclude study PREVPAC base pregnancy category clarithromycin Category C agent potential teratogenic abortifacient effect . These potential risk may also apply CRS/HIPEC . Assessed investigator unable unwilling comply requirement protocol ( e.g. , unable swallow pill ) Psychiatric addictive disorder condition , opinion investigator , would preclude patient meeting study requirement give informed consent Known active acute hepatitis confirm diagnosis Human Immunodeficiency Virus ( HIV ) infection . HIVpositive patient combination antiretroviral therapy ineligible . These patient increase risk lethal infection treat marrowsuppressive therapy . Active systemic infection require use parenteral antibiotic Renal insufficiency serum creatinine level ≥1.5 time upper limit normal calculated Patients concurrent severe medical problem unrelated malignancy preclude compliance study place unacceptable risk participation study determinate study investigator Patients maintain medication severe interaction PREVPAC</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pseudomyxoma Peritonei</keyword>
	<keyword>Appendiceal cancer</keyword>
	<keyword>CRS/HIPEC</keyword>
	<keyword>PMP</keyword>
</DOC>